Resultados da busca - Spring, Laura
- Mostrando 1 - 20 resultados de 29
- Ir para a próxima página
-
1
Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current stat... por Spring, Laura, Bardia, Aditya, Modi, Shanu
Publicado em 2016Texto -
2
-
3
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations por Spring, Laura M., Zangardi, Mark L., Moy, Beverly, Bardia, Aditya
Publicado em 2017Texto -
4
-
5
-
6
Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer por Karagounis, Theodora, Vallurupalli, Mounica, Nathan, Neera, Nazarian, Rosalynn, Vedak, Priyanka, Spring, Laura, Chen, Steven T.
Publicado em 2018Texto -
7
Sacituzumab Govitecan for Metastatic Triple‐Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities por Spring, Laura M., Nakajima, Erika, Hutchinson, Jennifer, Viscosi, Elene, Blouin, Gayle, Weekes, Colin, Rugo, Hope, Moy, Beverly, Bardia, Aditya
Publicado em 2021Texto -
8
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis por Spring, Laura M., Gupta, Arjun, Reynolds, Kerry L., Gadd, Michele A., Ellisen, Leif W., Isakoff, Steven J., Moy, Beverly, Bardia, Aditya
Publicado em 2016Texto -
9
Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series por Gazourian, Lee, Spring, Laura, Meserve, Emily, Hwang, David, Diaz, Alejandro A., Ash, Samuel Y., Ho, Vincent T., Sholl, Lynette M., Washko, George R.
Publicado em 2017Texto -
10
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic por Spring, Laura M., Specht, Michelle C., Jimenez, Rachel B., Isakoff, Steven J., Wang, Gary X., Ly, Amy, Shin, Jennifer A., Bardia, Aditya, Moy, Beverly
Publicado em 2020Texto -
11
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry por Smith, Barbara L., Nguyen, Anvy, Korotkin, Jenna E., Kelly, Bridget N., Specht, Michelle C., Spring, Laura M., Moy, Beverly, Isakoff, Steven J., Gadd, Michele A.
Publicado em 2020Texto -
12
Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer por Bychkovsky, Brittany L., Guo, Hao, Sutton, Jazmine, Spring, Laura, Faig, Jennifer, Dagogo-Jack, Ibiayi, Battelli, Chiara, Houlihan, Mary Jane, Yeh, Tsai-Chu, Come, Steven E., Lin, Nancy U.
Publicado em 2016Texto -
13
Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis por Spring, Laura M., Fell, Geoffrey, Arfe, Andrea, Sharma, Chandni, Greenup, Rachel, Reynolds, Kerry L., Smith, Barbara L., Alexander, Brian, Moy, Beverly, Isakoff, Steven J., Parmigiani, Giovanni, Trippa, Lorenzo, Bardia, Aditya
Publicado em 2020Texto -
14
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion por Mortensen, Lindsey, Ordulu, Zehra, Dagogo‐Jack, Ibiayi, Bossuyt, Veerle, Winters, Loren, Taghian, Alphonse, Smith, Barbara L., Ellisen, Leif W., Kiedrowski, Lesli A., Lennerz, Jochen K., Bardia, Aditya, Spring, Laura M.
Publicado em 2021Texto -
15
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer por Spring, Laura M., Clark, Shealagh L., Li, Tianyu, Goel, Shom, Tayob, Nabihah, Viscosi, Elene, Abraham, Elizabeth, Juric, Dejan, Isakoff, Steven J., Mayer, Erica, Moy, Beverly, Supko, Jeffrey G., Tolaney, Sara M., Bardia, Aditya
Publicado em 2021Texto -
16
Effectiveness and tolerability of neoadjuvant pertuzumab containing regimens for HER2-positive localized breast cancer. por Spring, Laura, Niemierko, Andrzej, Haddad, Stephanie, Yuen, Megan, Comander, Amy, Reynolds, Kerry, Shin, Jennifer, Bahn, Atul, Brachtel, Elena, Specht, Michelle, Smith, Barbara L., Taghian, Alphonse, Jimenez, Rachel, Peppercorn, Jeffrey, Isakoff, Steven J., Moy, Beverly, Bardia, Aditya
Publicado em 2018Texto -
17
FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer por Drago, Josh, Formisano, Luigi, Juric, Dejan, Niemierko, Andrzej, Servetto, Alberto, Wander, Seth, Spring, Laura, Vidula, Neelima, Peppercorn, Jeffrey, Younger, Jerry, Malvarosa, Giuliana, Yuen, Megan, Sgroi, Dennis, Isakoff, Steven J., Moy, Beverly, Ellisen, Leif W., Iafrate, John, Arteaga, Carlos L., Bardia, Aditya
Publicado em 2019Texto -
18
Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses por Koh, Siang-Boon, Dontchos, Brian N., Bossuyt, Veerle, Edmonds, Christine, Cristea, Simona, Melkonjan, Nsan, Mortensen, Lindsey, Ma, Annie, Beyerlin, Kassidy, Denault, Elyssa, Niehoff, Elizabeth, Hirz, Taghreed, Sykes, David B., Michor, Franziska, Specht, Michelle, Lehman, Constance, Ellisen, Leif W., Spring, Laura M.
Publicado em 2021Texto -
19
A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer por Kwan, Tanya T., Bardia, Aditya, Spring, Laura M., Giobbie-Hurder, Anita, Kalinich, Mark, Dubash, Taronish, Sundaresan, Tilak, Hong, Xin, LiCausi, Joseph A., Ho, Uyen, Silva, Erin J., Wittner, Ben S., Sequist, Lecia V., Kapur, Ravi, Miyamoto, David T., Toner, Mehmet, Haber, Daniel A., Maheswaran, Shyamala
Publicado em 2018Texto -
20
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy por Griffiths, Jason I., Chen, Jinfeng, Cosgrove, Patrick A., O’Dea, Anne, Sharma, Priyanka, Ma, Cynthia, Trivedi, Meghna, Kalinsky, Kevin, Wisinski, Kari B., O’Regan, Ruth, Makhoul, Issam, Spring, Laura M., Bardia, Aditya, Adler, Frederick R., Cohen, Adam L., Chang, Jeffrey T., Khan, Qamar J., Bild, Andrea H.
Publicado em 2021Texto